Presentation is loading. Please wait.

Presentation is loading. Please wait.

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Published byAriane Pothier Modified over 6 years ago

Similar presentations

Presentation on theme: "Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,"— Presentation transcript:

1 Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD, Akiko Kishi, MD  Journal of the American Academy of Dermatology  Volume 69, Issue 3, Pages (September 2013) DOI: /j.jaad Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Rash emergence, severity, and survival. Relationship between these in BR.21 study.11 CI, Confidence interval; HR, hazard ratio. Reprinted from Clinical Cancer Research 2007;13(13): , Wacker B et al, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies, with permission from AACR. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Acneiform rash and xeroderma. Characteristic symptoms.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Paronychia. Characteristic symptoms.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Grade ≥2 skin toxicity in patients with metastatic colorectal cancer (Skin Toxicity Evaluation Protocol with Panitumumab [STEPP] study), time to first occurrence.21 CI, Confidence interval; NR, not reached. Reprinted from Lacouture ME et al, Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer, Journal of Clinical Oncology 28(8):1351-7, with permission. © (2010) American Society of Clinical Oncology. All rights reserved. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Erlotinib-related skin disorders. Diagnosis and treatment.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

7 Fig 6 Application of topical creams and emollients: guidance on quantities for application. FTU, Fingertip unit. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

8 Fig 7 Procedure for using tape to treat paronychia.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

9 Fig 8 Procedure for removing nail plate and matrix in cases of paronychia. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,"

Similar presentations

Surgical margins for melanoma in situ

Surgical margins for melanoma in situ
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD 
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin.

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

Similar presentations

Ads by Google